en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span> <span lang="en-US" style="language:en-US">Globally, PD-1/PD-L1 inhibitors combined with bevacizumab have shown promising results in treating renal and lung cancers, but their efficacy in cervical cancer (CC) remains unclear. Superb microvascular imaging (SMI) is a novel technique for observing microcirculation in tumors. This study investigated the effectiveness and survival benefits of SMI in assessing tislelizumab combined with bevacizumab for treating CC. </span><span lang="en-US" style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods: </span></span></span></span></span><span lang="en-US" style="language:en-US">86 patients with CC (2022&ndash;2023) were randomly divided into two groups: group A (bevacizumab, n=43) and group B (tislelizumab + bevacizumab, n=43). After 4 cycles of treatment, tumor volume and Adler blood-flow grades were assessed using color Doppler flow imaging (CDFI) and SMI. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic value of both methods in assessing treatment effects. </span><span lang="en-US" style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span><span lang="en-US" style="language:en-US">Both CDFI and SMI demonstrated significant differences in treatment effectiveness between groups (p<0.05). CDFI showed improved Adler blood-flow grades after treatment in both groups (p<0.05), but they were not significantly different between the groups (P>0.05). SMI also revealed significant improvements (p<0.01) and greater differences between groups after treatment (p<0.05). The area under the curve (AUC) for SMI in evaluating therapeutic efficacy was 0.833 (sensitivity 86.05%, specificity 69.77%), while CDFI showed an AUC of 0.816 (sensitivity 79.07%, specificity 72.09%). </span><span lang="en-US" style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusions: </span></span></span></span></span><span lang="en-US" style="language:en-US">Tislelizumab combined with bevacizumab significantly improves CC treatment. SMI outperforms CDFI in evaluating tumor microvessels and provides valuable insight for the planning of early CC treatment.</span></span></span></span></span></span></span></div> Superb microvascular imaging, cervical cancer, monoclonal antibody, tislelizumab, bevacizumab. 619 625 http://ijrr.com/browse.php?a_code=A-10-1-1376&slc_lang=en&sid=1 L. Zhang 7900319475328460031511 7900319475328460031511 No Changzhou Cancer Hospital, Changzhou City, Jiangsu province, China H. Li 7900319475328460031512 7900319475328460031512 No Changzhou Cancer Hospital, Changzhou City, Jiangsu province, China C. Guo 7900319475328460031513 7900319475328460031513 No Changzhou Cancer Hospital, Changzhou City, Jiangsu province, China T. Cheng chengtao1216@hotmail.com 7900319475328460031514 7900319475328460031514 Yes Changzhou Cancer Hospital, Changzhou City, Jiangsu province, China